Judith Li is a Partner at Lilly Asia Ventures (LAV), a corporate venture capital firm founded in 2008 by Eli Lilly. See sector focus and contact routes.
Judith Li is a Partner at Lilly Asia Ventures (LAV), a corporate venture capital firm founded in 2008 by Eli Lilly, and she joined the firm in 2013 after prior experience at McKinsey and Partners Healthcare. She focuses on early- and growth-stage investments in biopharmaceuticals, medical devices, and diagnostics, with a cross-border thesis spanning the U.S. and Asia. While specific check sizes and lead/follow behavior are not publicly detailed, she is responsible for deal screening, due diligence, and post-investment portfolio management at LAV. Her notable portfolio companies include Inhibrx (acquired by Sanofi), TMunity (acquired by Gilead), Just Biotherapeutics (acquired by Evotec), and Structure. Li holds board appointments at several of these companies and also serves as a board director at ADARx Pharmaceuticals and Precede. She is recognized for bridging U.S.–Asia biotech investments and has held advisory and non-profit board roles, including as a non-executive director of the Hong Kong Venture Capital and Private Equity Association since 2017.
Details on this investor come from filing and round data held in the StartupFundraising directory, refreshed on ingest. Founders use profiles like this one to qualify fit and to shortlist investors in Hong Kong.
Investors like Judith Li · Full investor directory · Investor access · Company funding database